Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments (the eServices portal) close on Thursday 20 January at 4:30pm because of system upgrades. We expect to open them again on Friday 21 January at 8am the latest.

Eurostar project, AFFILUTIN, 9133, Affibody AB

Reference number
Coordinator Affibody AB
Funding from Vinnova SEK 4 435 470
Project duration October 2014 - September 2017
Status Ongoing
Venture Eurostars

Purpose and goal

Multiple myeloma is a non-curable blood cancer. In 2010 74.000 people died, globally, of the disease. The goal of this project is to make a new medicine, AFFILUTIN; that can treat multiple myeloma more efficiently and with less side effects than today’s treatments.

Expected results and effects

AFFILUTIN consists of a small protein molecule that binds specifically to a surface moiety of cancer cells, and a radioactive metal that will irradiate the cancer cells from within the body. AFFILUTIN will be injected into the blood of the patients and irradiate the cancer cells with minimal damage to surrounding healthy normal tissues.

Planned approach and implementation

Cancer cell targeting molecules are developed in iterative rounds of selection and optimization to create molecules with best possible binding properties for specific delivery of radiation. Promising tumour seeking capability of derived molecules is confirmed in an animal model of multiple myeloma, encouraging transition into expanded production and further analyses on their therapeutic effect in an animal model.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 19 March 2019

Reference number 2014-04000

Page statistics